Management Team
Duke Street Bio has an experienced and proven management team with an exceptional track record of delivering clinical molecules across therapeutic areas.
Peter Trill
Chairman
Dr Alan Wise
Chief Executive Officer
Dr Phill Cowley
Chief Scientific Officer
Dr Barry McGuinness
Chief Operating Officer
Dr Dónal Landers
Chief Medical Officer
Scientific Advisors
Duke Street Bio draws on the expertise and experience of its Scientific Advisory Board comprised of an extensive network of internationally-renowned scientists, physicians and key opinion leaders
Prof Johann De Bono
Head of Division of Clinical Studies, Institute for Cancer Research, London
Dr Elena Garralda
Director, Early Drug Development, Vall d’Hebron Institute of Oncology, Barcelona
Prof Timothy Yap
Medical Director,
Institute for Applied Cancer Science,
University of Texas
MD Anderson Cancer Center
Dr Jennifer Guerriero
Dana-Farber/Harvard Cancer Center,
Brigham and Women’s Hospital,
Harvard Medical School
Dr Elliott Sigal
Senior Advisor, New Enterprise Associates; Co-Chair SAB, Amgen; former CSO, Bristol Myers Squibb
Dr Christopher Hill
former Vice President,
Head of Global Chemistry, MSD
Prof Jason Luke
Director, Immunotherapy and Drug Development Center, UPMC Hillman Cancer Center and University of Pittsburgh
Prof Nicola Curtin
Professor of Experimental Cancer Therapeutics,
Newcastle University
Prof Ruth Plummer
Professor of Experimental
Cancer Medicine,
University of Newcastle
Prof Iain McNeish
Professor of Oncology, Imperial College London
Dr Rob Williams
Chief Drug Development
Scientist, CRUK
Dr Stefan Symeonides
CRUK Edinburgh Centre,
MRC Institute of Genetics & Molecular Medicine,
University of Edinburgh
Dr Ronan O'Hagan
CSO, Apricity Health;
former Executive Director, Oncology Discovery, MSD
Prof Jason Matthews
Professor, Department of Nutrition
University of Oslo, Department of Pharmacology & Toxicoloty
University of Toronto
Delivering life-saving cancer treatments to improve patient outcomes.